Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Biochemical safety and efficac...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

Bibliographic Details
Main Authors: Landray, M, Baigent, C, Leaper, C
Format: Conference item
Published: 2003
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
    by: Landray, M, et al.
    Published: (2006)
  • First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    by: Baigent, C, et al.
    Published: (2005)
  • Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
    by: Baigent, C, et al.
    Published: (2002)
  • Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
    by: Alexander, W, et al.
    Published: (2011)
  • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    by: Baigent, C, et al.
    Published: (2011)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs